Title: U.S. Emerging Lung Cancer Therapeutics Markets Novel Targeted Therapies Lower Side Effects
1U.S. Emerging Lung Cancer Therapeutics
MarketsNovel Targeted Therapies Lower Side
Effects
- "Standard doses of chemotherapy may prove to be
life threatening in the vast majority of lung
cancer patients. Novel targeted therapeutics in
combination with chemotherapy are expected to
make lung cancer more manageable and extend the
life of patients in stages three and four of the
disease."
Pharmaceuticals Analyst Team Frost Sullivan
2Key Features
- Detailed insights into recent developments and
trends - Drivers, restraints, challenges, and strategic
recommendations - Analytical insights into current topics and
emerging - applications in the lung cancer therapeutics
market - Market-sizing and competitive analysis
- Market forecasts and opportunity analyses
- Quarterly assessments
- End-user analysis
3What We Offer
- Coverage The United States
- Proven methodology using extensive primary and
secondary data as well as research - Focused information and strategies that cover
business and technology issues - Credible data and analyses that highlight
industry dynamics - Precise strategies to help you create winning
business plans
4Who Will Benefit?
- Current Market Participants
- Find out where you stand in comparison with the
competitors - Assess current and future drivers as well as
restraints - Determine and exploit new market share
opportunities - New Entrants
- Analyze the associated challenges
- Calculate timescales for strategy implementation
- Position yourself to capitalize on the unmet
needs of the market - Investment Community
- Analyze long-term strategies of companies
- Determine which participants will outperform the
competition - Assess the attractiveness of investing in the
market
5Key Market Participants
Abgenix Aeterna Laboratories, Inc. Allos
Therapeutics Aronex Astra-Zeneca
Pharmaceuticals Aventis Bristol-Myers
Squibb Celgene, Inc. Cell Pathways Eli
Lilly Entremed, Inc. Gaenera Corp. Glaxo-Smithklin
e Hoffmann La Roche IBC Pharmaceuticals,
Inc. Ilex Oncology
Imclone Systems, Inc. Immunex Corp. Immunogen,
Inc. Inex Pharmaceuticals Isis Ivax
Corp. Millennium Pharmaceuticals Novelos
Therapeutics OSI Pharma Pharmacia Corp. Ribozyme
Pharmaceuticals Sonus Pharmaceuticals Supergen,
Inc. Titan Pharma Zarix, Inc.
6For More Information
- Call toll free 877 GO FROST
- (877.463.7876)
- Fax toll free 888.690.3329
- E-mail myfrost_at_frost.com
- Visit www.frost.com